Latest News
-
Thursday - January 23, 2020
Bayer appoints Bijoy Sagar as new Chief Information Technology & Digital Transformation Officer
Daniel Hartert to leave Bayer after 12 years at the company » more
-
Thursday - January 23, 2020
Not intended for U.S. and UK Media
Bayer submits application to European Medicines Agency for pre-filled syringe to administer eye medication Eylea® » more
-
Thursday - January 23, 2020
Not intended for U.S. and UK Media
Bayer receives approval for darolutamide in Japan
Marketing authorization granted for the treatment of men with non-metastatic castration-resistant prostate cancer » more
-
Tuesday - January 21, 2020
Inclusion in the Bloomberg Gender-Equality Index
Bayer a global leader in diversity and inclusion » more
-
Monday - January 20, 2020
Not intended for U.S. and UK Media
Bayer to showcase new data including research in immuno- and precision oncology at ASCO GI Cancers Symposium 2020
Data to include early analyses of regorafenib across HCC, CRC and GI cancers, including Phase Ib data in combination with immuno-oncology therapies / New analysis of efficacy and safety from the NAVIGATE trial for larotrectinib in patients with TRK fusion cancer with gastrointestinal tumors will be presented » more
-
Monday - January 20, 2020
CDP publishes new ranking:
Bayer confirms leading international position as a sustainable company taking climate action
Chairman of the Board of Management, Baumann: “As a leading innovation company, we will drive forward a reduction in greenhouse gases throughout our entire value chain” / Numerous investors factor CDP ratings into investment decisions / Bayer listed as a leading company by CDP every year since 2005 » more
-
Thursday - January 16, 2020
Bayer and WuXi Biologics enter into an agreement on a Leverkusen drug product plant » more
-
Monday - January 13, 2020
Not intended for U.S. and UK Media
Bayer and Daré Bioscience enter into exclusive license agreement for U.S. commercial rights to investigational hormone-free, monthly contraceptive Ovaprene®
Underlining Bayer’s commitment in the field of women’s health / Potential commercial milestone payments of up to USD 310 million and tiered royalties on net sales in the double-digit range » more
-
Friday - January 10, 2020
Bayer and Azitra partner to harness the human skin microbiome as a source for new natural skin care products for sensitive and eczema-prone skin
Skin microbiome plays a crucial role in maintaining and restoring healthy human skin / Azitra targets skin “friendly” bacteria to solve the challenges of adverse skin conditions and diseases / Bayer to develop new natural skin care products based on suited skin microbiome bacteria » more
-
Thursday - January 9, 2020
Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery » more
-
Thursday - January 9, 2020
Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome
New five-year, multi-target alliance aims to translate first-in-class science and drug discovery into new drugs for polycystic ovary syndrome / Partners will have access to big data-driven target identification as highly promising approach via Evotec’s alliance with Celmatix Inc. / Milestone payments potentially more than EUR 330 million and EUR 16.5 million upfront and research payments » more
-
Tuesday - January 7, 2020
Bayer exercises right to enter into follow-on research and collaboration option agreement with Atomwise
Companies to continue crop protection development programs » more
-
Thursday - December 12, 2019
Bayer receives marketing authorization for Neptra® in Europe
The European Union has now granted marketing authorization for Neptra® ear drops solution for dogs in a centralized authorization procedure / Bayer's Neptra® treats susceptible strains of common pathogens found in canine otitis externa with just one vet-administered dose » more
-
Tuesday - December 10, 2019
Bayer to significantly step-up its sustainability efforts
2030 target to be carbon neutral in own operations / Ambitious 2030 objectives for access to health and nutrition in low- and middle-income countries and underserved communities / Measurable sustainability targets to be incorporated into management compensation » more
-
Wednesday - December 4, 2019
Digital transformation
New set-up for IT at Bayer
Specialized external partners to take over standardized IT services / Internal delivery to focus on IT activities that differentiate Bayer from its competitors » more
-
Friday - November 29, 2019
Bayer completes sale of Currenta stake to Macquarie Infrastructure and Real Assets
Further step in Bayer’s efforts to sharpen focus on core business » more
-
Thursday - November 28, 2019
Bayer selects Pharmaron as partner organization
Global collaboration for CMC development of small molecules » more
-
Monday - November 25, 2019
Not intended for U.S. and UK Media
Bayer submits application to EMA for use of rivaroxaban in children with venous thromboembolism
Adding treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children from birth to 17 years of age with confirmed VTE, including cerebral vein and sinus thrombosis / Submission based on results from phase 3 EINSTEIN-Jr. study showing convincing efficacy and safety profile for rivaroxaban in children with VTE / An oral liquid formulation of rivaroxaban that does not require injections and regular monitoring was developed to facilitate pediatric administration / Patent extension in Europe of six months will be applied for once the procedure is completed » more
-
Tuesday - November 19, 2019
Not intended for U.S. and UK Media - Neglected Tropical Diseases
Bayer expands collaboration with the World Health Organization to fight pork tapeworm infections as cause for epilepsy
5-year agreement on drug donation and financial support to treat infection with pork tapeworm T. solium (taeniasis) / Tissue infections in the brain caused by larvae of pork tapeworm / (neurocystercosis) are the most frequent cause of epilepsy in low- and middle-income countries / Control of taeniasis and neurocystercosis as cause of epilepsy in the focus of the new Neglected Tropical Diseases (NTD) Roadmap 2021 - 2030 of the World Health Organization » more
-
Monday - November 18, 2019
Not intended for U.S. and UK Media
Phase III VICTORIA study with vericiguat in patients with worsening chronic heart failure meets primary endpoint
Vericiguat reduced the risk of cardiovascular death or heart failure hospitalization versus placebo when given in combination with available heart failure therapies / Vericiguat is the first-in-class soluble guanylate cyclase stimulator being developed to treat patients with worsening chronic heart failure » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Thursday, February 27, 2020
Financial News Conference on the Full Year 2019 Results
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV